Stifel Financial Corp Buys 303,151 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Stifel Financial Corp lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 320.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 397,761 shares of the company's stock after buying an additional 303,151 shares during the period. Stifel Financial Corp owned about 0.39% of Intellia Therapeutics worth $4,638,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Sterling Capital Management LLC raised its stake in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics during the 4th quarter valued at about $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics in the fourth quarter valued at about $43,000. Jones Financial Companies Lllp grew its stake in Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after buying an additional 2,280 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock valued at $60,000 after acquiring an additional 2,299 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NTLA shares. Barclays dropped their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Truist Financial cut their price target on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Morgan Stanley cut shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $56.00 to $11.00 in a research report on Monday, January 27th. Chardan Capital reduced their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Finally, Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $36.68.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA traded down $0.47 during midday trading on Tuesday, reaching $7.98. 585,066 shares of the stock were exchanged, compared to its average volume of 2,416,312. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The company has a market capitalization of $826.07 million, a price-to-earnings ratio of -1.47 and a beta of 2.33. The business has a 50-day simple moving average of $8.30 and a two-hundred day simple moving average of $11.29.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.